

# Epidural dexamethasone showed a better analgesic profile over epidural betamethasone as adjuvant in acute neuropathic lumbar pain

Antonio T Kitayama, M.D, MSc<sup>1</sup>; Celia S Oliveira, M.D.<sup>1</sup>; Natalia V de Moraes, BSc, MSc, PhD<sup>2</sup>, Claudia R Lauretti, M.D., MSc, Ph.D.<sup>3</sup>, Helton A. Defino, M.D., MSc., Ph.D.<sup>4</sup>; Gabriela R. Lauretti, M.D.\*, M.Sc., Ph.D., FIPP<sup>5</sup>

<sup>1</sup>Postgraduate Students, School of Medicine of Ribeirão Preto, University of São Paulo (S.M.R.P.- U.S.P.), Brazil

<sup>2</sup>Department of Pharmaceutics, Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, Orlando – Lake Nona, U.S.A.

<sup>3</sup>Consultant in Ophthalmology, S.M.R.P.- U.S.P.

<sup>4</sup>Professor of Orthopedics, S.M.R.P.- U.S.P.

<sup>5</sup>Professor of Anesthesia and Interventional Pain Management, S.M.R.P.- U.S.P.

\*Corresponding author

Received: 25 Aug 2022,

Received in revised form: 15 Sep 2022,

Accepted: 20 Sep 2022,

Available online: 29 Sep 2022

©2022 The Author(s). Published by AI Publication. This is an open access article under the CC BY license (<https://creativecommons.org/licenses/by/4.0/>).

**Keywords—** epidural dexamethasone, epidural betamethasone, epidural lidocaine, acute neuropathic pain, ocular pressure.

**Abstract—** Background: The study was designed to evaluate dexamethasone and betamethasone as adjuvants in epidural management of acute radicular pain related to pain, ocular pressure, weight gain and systemic effects. Methods: Twenty six patients with neuropathic pain secondary to disc herniation acted as their own control related to the epidural administration of dexamethasone and betamethasone. Thirteen patients have started with dexamethasone during the first two weekly procedures, and after 3 weeks of wash-out were submitted to two weekly sequences of sacral betamethasone and cross-over. Patients were evaluated related to analgesia, blood pressure, ocular pressure, weight gain, adverse effects and plasmatic measurements of ions, glycemia, ACTH and cortisol. Results: Dexamethasone was superior to betamethasone analgesia ( $p<0.05$ ). Plasma cortisol and ACTH reduced on the 7<sup>th</sup> day after the block ( $p<0.001$ ). The plasmatic concentrations of the ions  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Ca}^{++}$ , control and post-prandial glycemia, blood pressure, weight were similar between groups and did not differ from initial control values ( $p>0.05$ ). Three patients that received dexamethasone after the first block and 2 that received betamethasone had cortisone glaucoma on day-7 ( $p<0.001$ ). Discussion: Epidural dexamethasone/lidocaine analgesia was superior to betamethasone/lidocaine analgesia and both drugs resulted in similar unaware increase in ocular pressure and sleep disturbance.

## I. INTRODUCTION

Although the indication of epidural corticosteroids as part of the treatment of acute neuropathic pain when the conservative treatment have failed is well recognized,<sup>1,2,3</sup> there have been concerns

related to which corticosteroid would be the best indication, as there is the risk of particulate aggregation and serious adverse effects secondary to their own pharmacological properties or intra vessel aggregation and obliteration.<sup>4,5,6</sup> Besides, there is no available information regarding the non-particulate dexamethasone or the

particulate betamethasone would offer better efficacy for analgesia effect. The study was aimed to evaluate their analgesic and systemic effects.

## II. METHODS

This clinical protocol and patient consent forms were designed in accordance with the revised Declaration of Helsinki and the Good Clinical Practice of the International Conference on Harmonization and approved by the Ethics Committee of the School of Medicine of Ribeirão Preto, University of São Paulo (USP) (Reg 14302010). Blood analysis was done at the Laboratory Center of Pharmacometry and Toxic Analysis, School of Pharmaceutical Sciences of the U.N.E.S.P., Araraquara. The prospective study was conducted at the Clinic for Pain Treatment- EPPA- Comprehensive Level, at the same hospital. Each patient acted as his/her own control after writing informed consent.

This prospective study comprised 26 consecutive patients at the Pain Center with clinical history of neuropathic lumbar pain (less than 3 months) secondary to disc herniation at L4-L5 or L5-S1, which diagnostic was based on clinical and magnetic resonance, who accept participating, who previously underwent conservative treatment with physical therapy under oral medication, albeit complaining of pain classified as VAS > 3 cm (VAS 0-10 cm).<sup>7</sup> The concept of visual analog scale (VAS), which consisted of a 10 cm line with 0 equaling “no pain at all” and 10 equaling “the worst possible pain” was introduced.

During this period, all patients were taking daily combination of 25 mg amitriptyline before bedtime, dipyrone three to four times daily and diclofenac 50 mg three times daily during the first 5 days. After introduction into the study, it was maintained only amitriptyline 25 mg and diclofenac was kept as rescue analgesic as part of the protocol. Subjects had to be willing and able (e.g. mental and physical condition) to participate in all aspects of the study, including use of medications, completion of evaluations, attending the scheduled clinic visit and compliance with protocol requirements as evidenced by providing written, informed consent. Patients were excluded from the study for the following reasons: evidence of clinically unstable disease, renal problems, glaucoma or history of glaucoma in the family, psychiatric disease, refusal or known allergy to the devices used, diabetes, previous cardiac infarction or angina, coagulation disturbance, or infection.

Patients acted as their own control related to the epidural administration of dexamethasone and betamethasone. Thirteen patients started with

dexamethasone during the first two weekly procedures (Dexa group (G)), and after 3 weeks of wash-out were submitted to two weekly sequence of sacral betamethasone (Beta G). The other patients have started with epidural betamethasone, followed by dexamethasone after 3-week rest. Patients were evaluated related to analgesia, blood pressure, ocular pressure, weight gain, adverse effects and plasmatic measurements of ions, glycaemia, ACTH and cortisol. Demographics characteristics were noted regarding all patients.

The caudal block was performed with either 10 mg dexamethasone or 10 mg betamethasone combined to 40 mg lidocaine diluted to final 10 ml volume with normal saline. The blocks were performed in the operating room with the aid of the fluoroscopy and non-iodinated contrast. Motorization for all patients consisted of non-invasive blood pressure, pulse oximetry and continuous electrocardiography. Patients were maintained on light sedation with 2 mg IV midazolam combined to 100 mcg IV alfentanil, administered in order to keep conscious sedation.

Blood pressure, ocular pressure (with Perkins tonometer, measured by the same ophthalmologist), weight (kg), pulse rate, plasmatic measurements of glycaemia, Na<sup>+</sup>, K<sup>+</sup> and Ca<sup>++</sup> were evaluated before each block during all the study period. Glycosylated hemoglobin was evaluated on days 1 and 35 (just before 1<sup>st</sup> and 3<sup>rd</sup> block, respectively, Figure 1). Plasmatic cortisol and adrenocorticotrophic hormone (ACTH) were evaluated on days 1, 7 and 35 for both drugs (Figure 1). However, only all 13 patients scheduled for the participation in the first part of the study were included for each drug evaluation related to cortisol and ACTH, after the administration of either dexamethasone during two consecutive weeks in 13 patients, or after the betamethasone administration in 13 patients.

Analgesia was evaluated by VAS pain scores (0-10 cm), and by number of rescue analgesic consumption. As rescue analgesics, it was prescribed 50 mg diclofenac at 8-hour interval if necessary (VAS > 3cm). Figure 2 describes the VAS measurements prior to first block during the two moments of the study after the 3-week wash-out period. For the VAS, all patients were included in the final evaluation for both drugs. The rescue analgesic consumption was equally evaluated in two times (days 14 and 49 of the study) including all patients. The VAS at day-7 reflected analgesia after the first block, while the VAS at day-14 reflected the analgesia after the 2<sup>nd</sup> block. Similarly, the VAS at day-42 reflected the analgesia after the third block (second moment of the study after wash-out period), and VAS at day-49 reflected the analgesia after

the 4<sup>th</sup> block (Figure 1). Rescue analgesic consumption was evaluated as mean daily tablet numbers at day-14 and

at day 49 for both groups.




Fig.1. Study organograma for pain evaluation




Fig.2. Organogram of the study related to blood collection and ocular pressure.

### III. STATISTICS

The power of the study was based upon preliminary data. We hypothesised that the dexamethasone analgesia would be 40% improved compared to epidural betamethasone. With a beta value of 80% and an alpha value of 0.05, these assumptions would require at least 18 patients.  $P < 0.05$  was considered significant. Data are expressed as mean $\pm$ STD, unless otherwise stated. The study included 26 patients to avoid bias..

The normality of the data was evaluated by the Shapiro Wilkings test. Demographic data was described. The statistical analysis was performed using Friedman and Wilcoxon signed-rank test. Significance was set at  $P < 0.05$ . Adverse effects were described.

### IV. RESULTS

The final data set included 23 subjects. One patient from Dexta G was excluded from the study due to

loss of blood material. The second patient excluded (from Beta G) did not come to receive the fourth block. Finally, a third patient from Dexta G refused to continue the study due to intense vaginal pruritus after the first block.

Thirteen patients were female and ten male. The mean time for pain prior to the study was  $3 \pm 1$  weeks. The variability of weight (kg) was similar when compared the weight before each block, at days 1, 7, 35 and 42 ( $p > 0.05$ ); independent of the phase of the study. The pain VAS prior to the study was  $8 \pm 2$  cm for the 23 patients. However, on day 7, patients from Dexta G showed lesser pain scores compared to the Beta G at both day-7 and day-14 (Day 7-  $3 \pm 1$  cm; *versus*  $5 \pm 1$  cm;  $p < 0.05$ ) (Day 14-  $2 \pm 1$  cm; *versus*  $3 \pm 2$  cm;  $p < 0.05$ ) (Figure 3). After 3 weeks wash-out, prior to start the second phase of the study protocol, the patient who have been previously during the first phase to the Dexta G showed lesser VAS scores showed lower scores compared to the first phase of Beta G during the day-35 ( $p < 0.05$ ). However, Figure 4 refers to the second phase of the study, and by the 42<sup>th</sup> and 49<sup>th</sup> days of the study, both groups were similar ( $p > 0.05$ ). Related to the number of rescue analgesics at day-14 and at day-49 for both groups, the Dexta G had a lower diclofenac rescue analgesic consumption 1(0-1) tablets (25% a 75%) and 2(2-3) (Beta G) at day 35 ( $p < 0.05$ ), however similar for both groups on 42<sup>th</sup> and 49<sup>th</sup> days.

Mean blood pressure was similar during all weeks of the study for all patients ( $p > 0.05$ , data not shown). Related to ocular pressure, 5 of 23 patients (22%) had cortisone glaucoma on day-7. The mean ocular pressure of those 5 patients prior to the study was  $13 \pm 2$  mmHg (similar to the others of the study group  $p > 0.05$ ). However, on the 7<sup>th</sup> day evaluation, the mean ocular pressure of the 5 patients was  $30 \pm 3$  mmHg ( $p < 0.001$ ). These patients were followed by a Glaucoma specialist, and all used beta-blocker eye drops to keep ocular pressure between 10-15 mmHg. However, one of the patients underwent trabeculectomy surgery.

The plasmatic concentration of  $\text{Na}^+$  (mean  $140 \pm 3$  mEq/l),  $\text{K}^+$  (mean  $4 \pm 0.3$  mEq/l)  $\text{Ca}^{++}$  (mean  $9.7 \pm 0.4$  mEq/l) fasting blood glucose ( $92 \pm 6$  mg/dl), blood glucose 120 minutes after food ingestion (mean  $114 \pm 7$  mg/dl), and glycated hemoglobin (mean  $5.2 \pm 0.3\%$ ) were similar during all study week evaluations ( $p > 0.05$ ).

The cortisol plasmatic concentrations ( $\mu\text{g/dl}$ ) were lower at day-7 compared to day-1 ( $p < 0.001$ ), but similar to day-35 ( $p > 0.05$ ) for both groups. Table 1 describes the plasmatic cortisol levels at 1<sup>st</sup>, 7<sup>th</sup> and 35<sup>th</sup> days for the Dexta G and Beta G. Table 2 describes the ACTH plasmatic levels (pg/dl) at 1<sup>st</sup>, 7<sup>th</sup> and 35<sup>th</sup> days ( $p < 0.01$ ) for the groups. Similarly, the ACTH plasmatic concentrations

were lower at day-7 compared to day-1 ( $p < 0.01$ ), but similar to day-35 for both groups ( $p > 0.05$ ).

Table 1. Plasmatic cortisol ( $\mu\text{g/dl}$ ) for Dexta G and Beta G at days 1<sup>st</sup>, 7<sup>th</sup> and 35<sup>th</sup>.

	Dexta G	Beta G
Day 1	$21.5 \pm 5.65$	$21.7 \pm 5.79$
Day 7	$11.5 \pm 4.07$	$11.2 \pm 3.32$
Day 35	$25.3 \pm 2.14$	$26.5 \pm 5.68$
P	1 <sup>st</sup> day > 7 <sup>th</sup> day 35 <sup>th</sup> day > 7 <sup>th</sup> day 1 <sup>st</sup> day = 35 <sup>th</sup> day	1 <sup>st</sup> day > 7 <sup>th</sup> day 35 <sup>th</sup> day > 7 <sup>th</sup> day 1 <sup>st</sup> day = 35 <sup>th</sup> day

Mean  $\pm$  STD. Dexta G- dexamethasone group; Beta G- betamethasone group

1<sup>st</sup> day > 7<sup>th</sup> day 1<sup>st</sup> day ( $p < 0.001$ ), but similar to 35<sup>th</sup> ( $p > 0.05$ ) for both groups

Table 2. Plasmatic ACTH (pg/dl) for Dexta G and Beta G at days 1<sup>st</sup>, 7<sup>th</sup> and 35<sup>th</sup>. day-7 It was lower at the 7<sup>th</sup> day compared to the 1<sup>st</sup> day ( $p < 0.01$ ), but similar to 35<sup>th</sup> day ( $p > 0.05$ ).

	Dexta G	Beta G
Day 1	$27.5 \pm 5.68$	$26.9 \pm 7.27$
Day 7	$15.3 \pm 2.86$	$15.8 \pm 4.39$
Day 35	$25.9 \pm 2.14$	$24.1 \pm 2.91$
P	1 <sup>st</sup> day > 7 <sup>th</sup> day 35 <sup>th</sup> day > 7 <sup>th</sup> day 1 <sup>st</sup> day = 35 <sup>th</sup> day	1 <sup>st</sup> day > 7 <sup>th</sup> day 35 <sup>th</sup> day > 7 <sup>th</sup> day 1 <sup>st</sup> day = 35 <sup>th</sup> day

Mean  $\pm$  STD. Dexta G- dexamethasone group; Beta G- betamethasone group

1<sup>st</sup> day > 7<sup>th</sup> day 1<sup>st</sup> day ( $p < 0.001$ ), but similar to 35<sup>th</sup> ( $p > 0.05$ ) for both groups

Related to adverse effects, one patient from Dexta G referred intense vaginal pruritus and felt uncomfortable, refusing to continue the study protocol. Another two patients from Beta G felt epigastralgia. Although 16 of 23 patients referred difficulty to sleep from the 1<sup>st</sup> -3<sup>rd</sup> day after sacral block, they did not take it as adverse effect, as they felt disposition during the following days. No others complain were noted.

## V. DISCUSSION

The results revealed that epidural 10 mg dexamethasone was clinically superior to epidural betamethasone related to analgesia, with similar adverse effects. The Dexta G showed less pain VAS scores during the study evaluation at day-7, day 14, day-42 and day 49



( $p < 0.05$ ). In addition, the Dexta G also showed lesser number of rescue analgesic consumption at day 14 and day-49 ( $p < 0.05$ ). Moreover, there was no change in weight and blood pressure during all study evaluation and no differences regarding the plasmatic concentration of  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Ca}^{++}$ , fasting blood glucose, blood glucose 120 minutes after food ingestion, and glycated hemoglobin during the study evaluation ( $p > 0.05$ ).

Recently, a systematic review of 26 total studies revealed that epidural steroids decreased the need for surgery as a primary outcome examined the same patient cohort.<sup>8</sup> In addition, we have decided for lidocaine, as an effect of crystallization has been described for the combination of ropivacaine and the non-particulate steroid dexamethasone.<sup>9</sup> Besides, 7 other meta-analysis studies demonstrated superior analgesic effect of lidocaine combined to steroids.<sup>10</sup> Apart from blocking presynaptic expression of functional Tetrodotoxin-Resistant  $\text{Na}^+$  channels and shaping presynaptic action potentials and transmitter release at the first sensory synapse,<sup>11</sup> spinal lidocaine may be involved preventing noxious stimuli by attenuating Nav1.3 up-regulation and suppressing activation of spinal microglia.<sup>12</sup> as well as inhibiting persistent  $\text{Na}^+$  current in the damaged dorsal ganglion.<sup>13</sup> Its effective anti-inflammatory action on neuropathic pain may also be secondary to lidocaine promotion of the suppressors of cytokine-signaling protein 3 expression in microglia, in turn suppressing IBA1<sup>+</sup> microglia accumulation and p38 MAPK and NF- $\kappa$ B.<sup>14</sup>

Corticosteroids been used frequently in pain treatments since 1952. Due to a review of the complications as a result of their application in epidural injections, the United States of America Food and Drug Administration issued an "alert controversy" requesting that a warning label should be added to injectable corticosteroids, where risks must be described, such as loss of sight, brain damage, paralysis and death) when administering by this route.<sup>15</sup> Even the time of preparation superior to 5 minutes may induce aggregation of betamethasone.<sup>17</sup> Nevertheless, epidural steroids are still a good option via the sacral route,<sup>16</sup> and dexamethasone was the nonparticulate steroid of choice.<sup>16</sup> Related to steroids, epidural dexamethasone had an attenuating effect on the peripheral inflammatory tissue injury induced hyperalgesia and this effect was mediated through the inhibition of intraspinal cytosolic phospholipase A<sub>2</sub> expression and the primary site of action was the laminae I-II of the spinal cord.<sup>18</sup> Moreover, dexamethasone treatment significantly reduced the levels of immune mediators, and prevented inflammatory and/or neurodegenerative lesions in the central and peripheral nervous systems, and apoptosis in the dorsal root ganglia.<sup>19</sup> There is also a suggestion that

dexamethasone could resolve brain inflammation possibly through microglial phenotypic switching from pro-inflammatory M1 to anti-inflammatory M2.<sup>20</sup>

Concerning the plasmatic evaluation, both the control levels of cortisol and ACTH were similar between groups prior to the study (Tables 1 and 2), but reduced at day-7 ( $p < 0.01$ ). However, at day-35, cortisol and ACTH levels returned to baseline in both groups ( $p > 0.05$ ), in accordance to others.<sup>21</sup> The ions  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Ca}^{++}$ , fasting plasma and post feeding plasma glucose were similar among groups when evaluated before each block for both groups ( $p > 0.05$ ). In accordance to others,<sup>22</sup> fasting glucose plasma levels was back to baseline values on the third day after the epidural administration of steroid, and after 2<sup>23</sup> to 4<sup>24</sup> days in diabetic patients. That would explain why our values were all back to baseline on day-7.

When the ocular pressure was evaluated, 3 patients from Dexta G and 2 from Beta G had an increase of ocular pressure on day-7 in the order of 30 mmHg, while normal ocular pressure is taken between 8 to 20 mmHg.<sup>25</sup> Corticosteroid glaucoma is directly linked to a corticosteroid treatment.<sup>26</sup> Among the risk factors it is described diabetes, myopia, young age; and the mode of steroid administration.<sup>25,27</sup> Increase in ocular pressure to 30 mmHg is taken clinically as corticosteroid glaucoma, and is described from 7 to 30 days after systemic steroids, with an incidence of 12.8%.<sup>27</sup> A different study suggested that patients over 51-year-old were more susceptible to increase ocular pressure after intravitreal dexamethasone.<sup>28</sup> Clinically, 4 of the patients had good response to eye drops, but one of them was submitted to trabeculectomy three months after the episode.

Apart from ocular pressure, other adverse effects were described although not statistically significant, albeit the power of the study was based on analgesia effect. One of the patients referred intense vaginal pruritus and was excluded from the study.<sup>29</sup> Its mechanism of action is not well known, its incidence is not significant, however its discomfort was considered catastrophic by the patient. Although 16 of 23 patients referred insomnia after the caudal steroid administration for up to three days, it was not taken as a problem by the patients, as they felt disposition during the day-time. That would justify the low incidence described by others.<sup>30</sup>

As conclusions, caudal dexamethasone combined to lidocaine resulted in superior analgesia compared to caudal betamethasone and lidocaine, and both drugs resulted in unaware increase in ocular pressure and sleep disturbance.

## ACKNOWLEDGMENTS

The authors thank CAPES-Brazil for financial support to make possible this project.

## REFERENCES

- [1] Lipetz J, Zelinger P, Kline M, Chahine N, Bloom O. Lumbar Radicular Pain Response to First Injection with Non-particulate Steroid. *Cureus*. 2020; 26:12:e7104.
- [2] Choi JH, Hong JY, Suh SW, et al. What Is the Role of Epidural Steroid Injections in Lumbar Spinal Disease with Moderate Disability? *Pain Physician*. 2016;19:293-298.
- [3] Ter Meulen BC, Maas ET, Vyas A, et al. Treatment of acute sciatica with transforaminal epidural corticosteroids and local anesthetic: design of a randomized controlled trial. *BMC Musculoskelet Disord*. 2017;25:18:215.
- [4] Wahezi SE, Lederman A, Algra J, et al. Human Serum Modifies Aggregation Properties of Commonly Used Epidural Steroids. *Pain Physician*. 2015;18:1131-1138.
- [5] Gazelka HM, Burgher AH, Huntoon MA, et al. Determination of the particulate size and aggregation of clonidine and corticosteroids for epidural steroid injection. *Pain Physician*. 2012;15:87-93.
- [6] Choi EJ, Kim DH, Han WK, Lee HJ, Kang I, Nahm FS, Lee PB. Non-Particulate Steroids (Betamethasone Sodium Phosphate, Dexamethasone Sodium Phosphate, and Dexamethasone Palmitate) Combined with Local Anesthetics (Ropivacaine, Levobupivacaine, Bupivacaine, and Lidocaine): A Potentially Unsafe Mixture. *J Pain Res* 2021;14:1495-1504.
- [7] Goncharov DI, Zagorul'ko OI, Medvedeva LA, et al. Epidural blockades use in low back pain treatment. *Anesteziol Reanimatol*. 2014;;72-76.
- [8] Bicket MC, Horowitz JM, Benzon HT, Cohen SP. Epidural injections in prevention of surgery for spinal pain: systematic review and meta-analysis of randomized controlled trials. *Spine J*. 2015;15:348-362.
- [9] Watkins TW, Dupre S, Coucher JR. Ropivacaine and dexamethasone: a potentially dangerous combination for therapeutic pain injections. *J Med Imaging Radiat Oncol*. 2015;59:571-577.
- [10] Manchikanti L, Knezevic NN, Boswell MV et al. Epidural Injections for Lumbar Radiculopathy and Spinal Stenosis: A Comparative Systematic Review and Meta-Analysis. *Pain Physician*. 2016;19:365-410.
- [11] Medvedeva YV, Kim MS, Schnizler K, Usachev YM. Functional tetrodotoxin-resistant Na(+) channels are expressed presynaptically in rat dorsal root ganglia neurons. *Neuroscience*. 2009;159:559-569.
- [12] Cheng KI, Lai CS, Wang FY, et al. Intrathecal lidocaine pretreatment attenuates immediate neuropathic pain by modulating Nav1.3 expression and decreasing spinal microglial activation. *BMC Neurol*. 2011;11:71.
- [13] Dong H, Fan YH, Wang YY, et al. Lidocaine suppresses subthreshold oscillations by inhibiting persistent Na(+) current in injured dorsal root ganglion neurons. *Physiol Res*. 2008;57:639-645.
- [14] Zheng Y, Hou X, Yang S. Lidocaine Potentiates SOCS3 to Attenuate Inflammation in Microglia and Suppress Neuropathic Pain. *Cell Mol Neurobiol*. 2019;39:1081-1092.
- [15] Orduña-Valls JM, Nebreda-Clavo CL, López-Pais P, et al. Characteristics of particulate and non-particulate corticosteroids. Indications for their use in chronic pain treatments. *Rev Esp Anestesiol Reanim*. 2016;63:333-346.
- [16] Mallinson PI, Tapping CR, Bartlett R, Maliakal P. Factors that affect the efficacy of fluoroscopically guided selective spinal nerve root block in the treatment of radicular pain: a prospective cohort study. *Can Assoc Radiol J*. 2013;64:370-375.
- [17] Orduña-Valls JM, David L Cedeno DL, Nebreda-Clavo C, Tornero-Tornero C, Alvarez-Escudero J, Martinez MF, Valverde-Navarro AA, Ruiz-Sauri A. Microscopic Study of Injectable Steroids: Effects of Postmixing Time on Particle Aggregation. *Pain Physician* 2020;23(4):E417-E424.
- [18] Benzon HT, Chew TL, McCarthy RJ, et al. Comparison of the particle sizes of different steroids and the effect of dilution: a review of the relative neurotoxicities of the steroids. *Anesthesiology*. 2007;106:331-338.
- [19] Min SH, Soh JS, Park JY, et al. Epidural dexamethasone decreased inflammatory hyperalgesia and spinal cPLA<sub>2</sub> expression in a rat formalin test. *Yonsei Med J*. 2014;55:1631-1639.
- [20] Dey R, Bishayi B. Dexamethasone exhibits its anti-inflammatory effects in *S. aureus* induced microglial inflammation via modulating TLR-2 and glucocorticoid receptor expression. *Int Immunopharmacol*. 2019;75:105806.
- [21] Ramesh G, Meisner OC, Philipp MT. Anti-inflammatory effects of dexamethasone and meloxicam on *Borrelia burgdorferi*-induced inflammation in neuronal cultures of dorsal root ganglia and myelinating cells of the peripheral nervous system. *J Neuroinflammation*. 2015;12:240.
- [22] Chutatape A, Menon M, Fook-Chong S, George JM. Metabolic and endocrinal effects of epidural glucocorticoid injections. *Singapore Med J*. 2019;60:140-144.
- [23] Moon HJ, Choi KH, Lee SI, et al. Changes in blood glucose and cortisol levels after epidural or shoulder intra-articular glucocorticoid injections in diabetic or nondiabetic patients. *Am J Phys Med Rehabil*. 2014;93:372-378.
- [24] Gonzalez P, Laker SR, Sullivan W, et al. The effects of epidural betamethasone on blood glucose in patients with diabetes mellitus. *PM R*. 2009;1:340-345.
- [25] Kim WH, Sim WS, Shin BS, et al. Effects of two different doses of epidural steroid on blood glucose levels and pain control in patients with diabetes mellitus. *Pain Physician*. 2013;16:557-568.
- [26] Roberti G, Oddone F, Agnifili L, Katsanos A, Michelessi M, Mastropasqua L, Quaranta L5, Riva I, Tanga L, Manni G. Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. *Surv Ophthalmol*. 2020;65:458-472.
- [27] Bremer F. Origin of corticosteroid glaucoma. *Bull Soc Belge Ophthalmol*. 2007;304:111-116.
- [28] Choi W, Bae HW, Choi EY, Kim M, Kim EW, Kim CY, Kim M, Seong GJ. Age as a risk factor for steroid-induced

ocular hypertension in the non-paediatric population. Br J Ophthalmol. 2020. pii: bjophthalmol-2019-314559.

- [29] El Abd O, Pimentel DC, Amadera JE. Generalized pruritus as an unusual side effect after epidural injection with dexamethasone. PM R. 2015;7:206-209.

- [30] Plastaras C, McCormick ZL, Garvan C, et al. Adverse events associated with fluoroscopically guided lumbosacral transforaminal epidural steroid injections. Spine J. 2015;15:2157-2165.




Fig.3. Pain VAS scores (0-10 cm) for groups Dexa G and Beta G just prior of the block.  $P < 0.05$  at 1<sup>st</sup>, 7<sup>th</sup> and 14<sup>th</sup> –day Dexamethasone group < Betamethasone group at days 7<sup>th</sup> and 14<sup>th</sup> ( $p < 0.05$ ).




Fig4. After the wash-out, the cross-over of the groups. Pain VAS scores (0-10 cm) for groups DexaG and Beta G. Dexa G < Beta G at 35<sup>th</sup> day ( $p < 0.05$ ).